- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Koning Corporation Launches AI Software for 3D Breast CT
The artificial intelligence (AI) software facilitates high-resolution three-dimensional computed tomography (CT) images of the breast.
Could three-dimensional (3D) computed tomography (CT) be a game changer for early detection of breast cancer?
Koning Corporation has announced the launch of adjunctive artificial intelligence (AI) software that can produce 3D CT breast images through seamless integration with the company’s existing breast CT devices.
In addition to the high-resolution 3D images, Koning said the AI software provides significant noise and artifact reductions.
The company said the technological advancements with the new proprietary AI software may facilitate earlier detection of breast cancer.
“We are proud to introduce this revolutionary AI-enhanced breast CT software. This update to our current platform is set to redefine the standards of image quality in breast CT imaging, empowering radiologists to detect even the smallest irregularities at the earliest stages,” noted Lutao Ning, the chief executive officer of Koning.
(Editor’s note: For related content, see “Positron Emission Tomography: De-Escalation of Breast Cancer Treatment: What Emerging Research Reveals” and “Ultravist Becomes First FDA-Approved Contrast Agent for Contrast-Enhanced Mammography.”)
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
